Trials / Recruiting
RecruitingNCT07146022
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 552 (estimated)
- Sponsor
- Veradermics, Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Detailed description
Not required.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VDPHL01 QD | VDPHL01 Extended Release (ER) Tablet |
| DRUG | Placebo | Placebo tablet |
| DRUG | VDPHL01 BID | VDPHL01 Extended Release (ER) Tablet |
| DRUG | Placebo | Placebo tablet |
Timeline
- Start date
- 2025-07-25
- Primary completion
- 2027-06-01
- Completion
- 2028-01-01
- First posted
- 2025-08-28
- Last updated
- 2025-11-24
Locations
71 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07146022. Inclusion in this directory is not an endorsement.